CYTK
Income statement / Annual
Last year (2023), Cytokinetics, Incorporated's total revenue was $7.53 M,
a decrease of 92.04% from the previous year.
In 2023, Cytokinetics, Incorporated's net income was -$526.24 M.
See Cytokinetics, Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$7.53 M
|
$94.59 M
|
$70.43 M
|
$55.83 M
|
$26.87 M
|
$31.50 M
|
$13.37 M
|
$106.41 M
|
$28.66 M
|
$46.94 M
|
| Cost of Revenue |
$11.89 M |
$240.81 M |
$159.94 M |
$96.95 M |
$86.13 M |
$89.14 M |
$90.30 M |
$59.90 M |
$46.40 M |
$44.43 M |
| Gross Profit |
-$4.36 M |
-$146.23 M |
-$89.51 M |
-$41.12 M |
-$59.26 M |
-$57.63 M |
-$76.93 M |
$46.51 M |
-$17.74 M |
$2.51 M |
| Gross Profit Ratio |
-0.58 |
-1.55 |
-1.27 |
-0.74 |
-2.21 |
-1.83 |
-5.75 |
0.44 |
-0.62 |
0.05 |
| Research and Development
Expenses |
$318.23 M
|
$6.59 M
|
$159.94 M
|
$96.95 M
|
$86.13 M
|
$89.14 M
|
$90.30 M
|
$59.90 M
|
$46.40 M
|
$44.43 M
|
| General & Administrative
Expenses |
$173.61 M
|
$177.98 M
|
$96.80 M
|
$52.82 M
|
$39.61 M
|
$31.28 M
|
$36.47 M
|
$27.82 M
|
$19.67 M
|
$17.27 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$173.61 M
|
$177.98 M
|
$96.80 M
|
$52.82 M
|
$39.61 M
|
$31.28 M
|
$36.47 M
|
$27.82 M
|
$19.67 M
|
$17.27 M
|
| Other Expenses |
$326.09 M |
-$6.59 M |
-$159.94 M |
-$96.95 M |
-$86.13 M |
$0.00 |
$0.00 |
$58.66 M |
$31.73 M |
$24.89 M |
| Operating Expenses |
$491.84 M |
$177.98 M |
$96.80 M |
$52.82 M |
$39.61 M |
$31.28 M |
$36.47 M |
$27.82 M |
$19.67 M |
$17.27 M |
| Cost And Expenses |
$503.74 M |
$418.79 M |
$256.74 M |
$149.77 M |
$125.74 M |
$120.42 M |
$126.76 M |
$87.72 M |
$66.07 M |
$61.69 M |
| Interest Income |
$27.63 M |
$11.34 M |
$331,000.00 |
$5.33 M |
$4.54 M |
$4.19 M |
$2.60 M |
-$2.23 M |
-$94,000.00 |
$108,000.00 |
| Interest Expense |
$57.67 M |
$51.16 M |
$29.33 M |
$38.68 M |
$27.36 M |
$21.56 M |
$17.00 M |
$2.23 M |
$94,000.00 |
-$108,000.00 |
| Depreciation &
Amortization |
$11.89 M
|
$8.40 M
|
$9.64 M
|
$1.83 M
|
$1.29 M
|
$1.24 M
|
$1.90 M
|
$741,000.00
|
$589,000.00
|
$490,000.00
|
| EBITDA |
-$484.31 M
|
-$312.86 M
|
-$185.98 M
|
-$88.61 M
|
-$93.04 M
|
-$84.73 M
|
-$110.79 M
|
$18.69 M
|
-$37.41 M
|
-$14.75 M
|
| EBITDA Ratio |
-64.32 |
-3.31 |
-2.64 |
-1.59 |
-3.46 |
-2.69 |
-8.29 |
0.18 |
-1.31 |
-0.31 |
| Operating Income Ratio
|
-65.9
|
-3.43
|
-2.65
|
-1.68
|
-3.68
|
-2.82
|
-8.48
|
0.18
|
-1.31
|
-0.31
|
| Total Other
Income/Expenses Net |
-$30.04 M
|
-$64.75 M
|
-$29.00 M
|
-$33.35 M
|
-$22.83 M
|
-$17.37 M
|
-$14.39 M
|
-$2.23 M
|
-$94,000.00
|
$108,000.00
|
| Income Before Tax |
-$526.24 M |
-$388.96 M |
-$215.31 M |
-$127.29 M |
-$121.69 M |
-$106.29 M |
-$127.79 M |
$16.45 M |
-$37.50 M |
-$14.65 M |
| Income Before Tax Ratio
|
-69.89
|
-4.11
|
-3.06
|
-2.28
|
-4.53
|
-3.37
|
-9.56
|
0.15
|
-1.31
|
-0.31
|
| Income Tax Expense |
$11.72 M |
$13.60 M |
$27.06 M |
$36.85 M |
$27.36 M |
$4.19 M |
$682,000.00 |
-$741,000.00 |
-$589,000.00 |
-$490,000.00 |
| Net Income |
-$526.24 M |
-$402.55 M |
-$242.37 M |
-$164.14 M |
-$149.05 M |
-$106.29 M |
-$127.79 M |
$16.45 M |
-$37.50 M |
-$14.65 M |
| Net Income Ratio |
-69.89 |
-4.26 |
-3.44 |
-2.94 |
-5.55 |
-3.37 |
-9.56 |
0.15 |
-1.31 |
-0.31 |
| EPS |
-5.45 |
-4.48 |
-3.15 |
-2.54 |
-2.59 |
-1.95 |
-2.59 |
0.41 |
-0.97 |
-0.41 |
| EPS Diluted |
-5.45 |
-4.48 |
-3.15 |
-2.54 |
-2.59 |
-1.95 |
-2.59 |
0.39 |
-0.97 |
-0.41 |
| Weighted Average Shares
Out |
$96.52 M
|
$89.83 M
|
$76.89 M
|
$64.52 M
|
$57.58 M
|
$54.42 M
|
$49.40 M
|
$39.94 M
|
$38.66 M
|
$35.71 M
|
| Weighted Average Shares
Out Diluted |
$96.52 M
|
$89.83 M
|
$76.89 M
|
$64.52 M
|
$57.58 M
|
$54.42 M
|
$49.40 M
|
$42.56 M
|
$38.81 M
|
$35.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
